title: Mitogenic signalling in the absence of epidermal growth factor receptor activation in a human glioblastoma cell line.
abstract: Epidermal growth factor receptor (EGFR) gene amplification and overexpression are commonly present in glioblastoma, and confer advantages of growth, invasiveness and radio/chemotherapy-resistance for tumour cells. Here, we assessed the role of EGFR activation for downstream mitogenic signalling in the commonly used glioblastoma cell line U251. Despite the high expression level, activation of EGFR under standard culture conditions was low. Intact EGFR function was verified by the rapid phosphorylation of EGFR and downstream mitogen-activated protein(MAP) kinase ERK1/2 upon addition of exogenous EGF to serum-starved cells. By contrast, addition of fetal bovine serum (FBS) activated downstream ERK1/2 via the MAP kinase kinase without phosphorylating EGFR. A phosphoreceptor tyrosine kinase array showed FBS-induced activation of insulin-like growth factor-1 receptor (IGF-1R),and the IGF-1R inhibitor AG1024 inhibited FBS-induced phosphorylation of ERK1/2, implying IGF-1R as the major driver of FBS-associated mitogenic signalling in the absence of exogenous EGF. These findings have important implications for in vitro drug testing in glioblastoma. Moreover, activation of ERK1/2 was also strongly influenced by growth state and cell density of U251 cultures. Re-seeding exponentially growing cultures at high cell density induced p27/CDKN1B expression and suppressed P-ERK1/2 indicating a certain regulation of proliferation by contact inhibition. Strikingly, highly activated ERK1/2 signalling and cell cycle progression occurred when cells were released from plateau phase regardless of high seeding density. This phenomenon might implicate a proliferation response in the early recurrence observed after clinical therapy in glioblastoma patients. However, whether it will recapitulate in vivo remains to be demonstrated.
authors.forename: Meng
authors.initials: M
authors.lastname: Wang
authors.forename: Patrick
authors.initials: P
authors.lastname: Maier
authors.forename: Frederik
authors.initials: F
authors.lastname: Wenz
authors.forename: Frank Anton
authors.initials: FA
authors.lastname: Giordano
authors.forename: Carsten
authors.initials: C
authors.lastname: Herskind
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002417:Cattle; D066246:ErbB Receptors / Q000378:metabolism*; D005909:Glioblastoma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D010766:Phosphorylation; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D044967:Serum / Q000378:metabolism; D015398:Signal Transduction; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors; D017526:Receptor, IGF Type 1; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
references.citation: Cancer Res. 2002 Jan 1;62(1):200-7
references.pmid: 11782378
references.citation: Endocr Relat Cancer. 2001 Sep;8(3):151-9
references.pmid: 11566606
references.citation: J Clin Oncol. 2009 Feb 1;27(4):579-84
references.pmid: 19075262
references.citation: J Biol Chem. 2009 Mar 13;284(11):7138-48
references.pmid: 19147502
references.citation: Clin Cancer Res. 2008 Feb 15;14(4):957-60
references.pmid: 18281526
references.citation: Oncogene. 2005 Nov 14;24(50):7435-42
references.pmid: 16288290
references.citation: Am J Pathol. 2007 May;170(5):1445-53
references.pmid: 17456751
references.citation: Semin Oncol. 2004 Oct;31(5):595-604
references.pmid: 15497113
references.citation: FEBS Lett. 2005 Mar 21;579(8):1891-5
references.pmid: 15763569
references.citation: Bioessays. 2000 Sep;22(9):818-26
references.pmid: 10944584
references.citation: J Biol Chem. 1996 Nov 1;271(44):27456-61
references.pmid: 8910327
references.citation: Brain Pathol. 1999 Jul;9(3):469-79
references.pmid: 10416987
references.citation: Curr Opin Cell Biol. 2006 Oct;18(5):463-71
references.pmid: 16919434
references.citation: Strahlenther Onkol. 2010 Jan;186(1):1-6
references.pmid: 20082181
references.citation: J Cell Sci. 2000 Dec;113 Pt 23:4221-30
references.pmid: 11069767
references.citation: Oncogene. 2007 May 14;26(22):3227-39
references.pmid: 17496918
references.citation: J Neurooncol. 2009 Apr;92(2):137-47
references.pmid: 19043776
references.citation: J Neurosci Res. 2002 Apr 15;68(2):150-60
references.pmid: 11948660
references.citation: J Biol Chem. 2008 Apr 18;283(16):10958-66
references.pmid: 18292095
references.citation: Biochim Biophys Acta. 2006 Aug;1766(1):1-22
references.pmid: 16844299
references.citation: Expert Opin Ther Targets. 2007 Apr;11(4):463-72
references.pmid: 17373877
references.citation: J Cell Physiol. 2009 Mar;218(3):460-6
references.pmid: 19006176
references.citation: J Cell Biol. 1998 Nov 30;143(5):1375-83
references.pmid: 9832564
references.citation: Cancer Res. 2009 May 15;69(10):4167-74
references.pmid: 19435897
references.citation: Cancer Lett. 2003 Dec 8;202(1):43-51
references.pmid: 14643025
references.citation: Radiat Res. 2006 Sep;166(3):463-73
references.pmid: 16953664
references.citation: FEBS J. 2006 Dec;273(23):5231-44
references.pmid: 17064312
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6364-70
references.pmid: 18927274
references.citation: Cancer Res. 2002 Jul 15;62(14):4142-50
references.pmid: 12124353
references.citation: Int J Cancer. 2009 Jun 1;124(11):2719-27
references.pmid: 19199360
references.citation: Cell. 1995 Feb 24;80(4):661-70
references.pmid: 7867073
references.citation: Cancer Res. 2010 Oct 1;70(19):7500-13
references.pmid: 20858720
references.citation: J Oncol. 2010;2010:
references.pmid: 20953359
references.citation: Trends Pharmacol Sci. 1999 Oct;20(10):408-12
references.pmid: 10577253
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Front Oncol. 2012 Apr 10;2:31
references.pmid: 22645717
references.citation: J Neurooncol. 2010 May;98(1):93-9
references.pmid: 19960228
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1268-74
references.pmid: 19204207
references.citation: Radiat Res. 2003 Mar;159(3):283-300
references.pmid: 12600231
references.citation: N Engl J Med. 2005 Nov 10;353(19):2012-24
references.pmid: 16282176
references.citation: J Neurosci. 2003 May 15;23(10):4208-18
references.pmid: 12764109
references.citation: Trends Biochem Sci. 2008 Aug;33(8):356-9
references.pmid: 18585043
references.citation: Radiother Oncol. 2009 Sep;92(3):316-22
references.pmid: 19615770
references.citation: J Neurooncol. 2008 Oct;90(1):89-97
references.pmid: 18581057